Article Text

PDF
GW24-e0232 Effects of cardiac shock wave therapy on the angiogenesis related cytokine of CAD patients
  1. Yang Ping1,
  2. Guo Tao2,
  3. Peng Yun-zhu2,
  4. Wang Yu2,
  5. Cai Hong-yan2
  1. 1Department of Cardiology, The First People’s Hospital of Kunming, Kumming, Yunnan, China.
  2. 2Department of Cardiology, 1st Affiliated Hospital of Kumming Medical University, Kumming, Yunnan, China

Abstract

Objectives To explore the effects of Cardiac Shock Wave Therapy (CSWT) on the angiogenesis Related Cytokine of CAD Patients.

Methods A total of 87 patients with old myocardial infarction (OMI) were enrolled in this study who received treatment in Department of Cardiology, 1st Affiliated Hospital of Kunming Medical University from October 2008 to January 2011, 68 male and 19 female, aged from 43 to 80 years (66.80 ± 8.41 years). The patients were divided into different group, Group A enrolled 32 cases (24 male, 8 female, 68.31 ± 8.72 years), Group B enrolled 30 cases (24 male, 6 female, 65.67 ± 8.33 years). Patients in Group A received 9 spots treatment of each ischaemia target region (-1, 0, +1 pairs), patients in Group B received 25 spots treatment of each ischaemia target region (-2, -1, 0, +1, +2 pairs), 200 shocks/spot, 3 times/week, during the first week of each month on the first, third, and fifth day for 3 months for a total of 9 therapies per patient. And 25 patients were in the control group (Group C, 20 male, 5 female, 66.24 ± 8.14 years). Group C treated with the same procedures but without the shock wave energy by using randomised single-blind method. Before the CSWT (0 month) and the follow-up of 3 months, 6 months, 12 months, all patients collected 5 ml fasting in peripheral venous blood, then centrifugate the blood within 2 hours (3000 r/min,15 min), collected serum then stored in -80° freezer for using. Used ELISA method to test the serum concentration of eNOS, bFGF, SDF–1, CXCR4 for patients.

Results Before the CSWT there was no significant difference for each assessing parameter include serum eNOS, bFGF, SDF–1, CXCR4 among three groups (P > 0.05). Follow–up to 3 months, the above mentioned parameters of patients in Group A and B compared with 0 month respectively improved significantly (P < 0.05), Follow–up to 6 months, the above mentioned parameters compared with 0 month and 3 month of patients in Group A and B improved significantly (P < 0.05), follow-up to 12 months, eNOS, SDF–1, CXCR4 of Group A compared with 0 month and 3 months improved significantly (P < 0.05), compared with 6 months the differences have no statistical significance (P > 0.05), for bFGF compared with 0 month, 3 months, 6 months improved significantly (P < 0.05); And bFGF, SDF–1, CXCR4 of Group B compared with 0 month, 3 months, 6 months improved significantly (P < 0.05), the eNOS compared with 0 month, 3 months improved significantly (P < 0.05), compared with 6 months the differences have no statistical significance (P > 0.05). In the follow–up, the above mentioned parameters of Group B improved significantly compared with the same period of Group A (P < 0.05), and the follow–up of patients in Group A and B of 3 months, 6 months, 12 months, the above mentioned parameters compared with the same period of Group C improved significantly (P < 0.05). The follow–up to 12 months of Group C, the above mentioned parameters compared with 0 month, 3 months, 6 months decreased significantly (P < 0.05).

Conclusions

  1. CSWT can promote the expression of eNOS,bFGF, SDF–1and its receptor CXCR4.

  2. 25 points expanding the range treatment of CSWT can be more continuously and effectively promote the expression of eNOS, bFGF, SDF–1 and its receptor CXCR4 than 9 points treatment.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.